I-Corps: Single-domain antibody platform to develop cancer immunotherapies for the treatment of both canine and human cancers

I-Corps：单域抗体平台，用于开发治疗犬类和人类癌症的癌症免疫疗法

• 批准号: 2040609
• 负责人: Christopher Cebra
• 金额: $ 5万
• 依托单位: Oregon State University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2022-01-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2040609&HistoricalAwards=false
• 关键词: Corps; Single; domain; antibody; platform

The broader impact/commercialization potential of this I-Corps project is the development and translation of a drug discovery platform for the treatment of both canine and human cancers. The proposed technology defines the requirements for harnessing the ability of immune-based cancer therapies to target and eradicate cancer with a drug platform that may be manipulated to create new and powerful therapies. Developing immune-based cancer therapies may result in the production of a number of cost effective and safe treatments that may be easily administered to patients, potentially making a significant commercial impact. The proposed technology is expected to translate the understanding of cancer progression using the dog as an animal model for clinical investigations. This approach would be a first for canine therapies and is expected to impact development of human cancer therapeutics.This I-Corps project is based on the development of a single-domain antibody platform to develop cancer immunotherapies for the treatment of both canine and human cancers. Cancer immunotherapies based on a single-domain antibody platform have yet to be approved for human use and the development of the proposed canine agents may provide valuable insight into the pharmacologic behavior of this type of agent in the appropriate disease setting. In addition, physically combining single-domain antibodies with other cancer treatment agents, may add a novel way immune molecules may be used to fight cancer growth. The proposed technology has the potential to result in tailored cancer therapies for patients of all types. Thus, this advancement of the state-of-the-art has the potential to quickly bring novel, effective products to all cancer-patients, with marked potential for high commercial and societal impact.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

I-Corps项目更广泛的影响/商业化潜力是开发和翻译用于治疗犬类和人类癌症的药物发现平台。拟议的技术定义了利用基于免疫的癌症疗法的能力来靶向和根除癌症的药物平台的要求，该平台可以被操纵来创造新的强大的疗法。开发基于免疫的癌症疗法可能导致生产一些成本效益高且安全的治疗方法，这些治疗方法可能容易给患者使用，可能产生重大的商业影响。这项拟议的技术有望将对癌症进展的理解转化为使用狗作为临床研究的动物模型。这种方法将首次用于犬类治疗，并有望影响人类癌症治疗的发展。I-Corps项目的基础是开发单域抗体平台，开发用于治疗犬类和人类癌症的癌症免疫疗法。基于单域抗体平台的癌症免疫疗法尚未被批准用于人类，拟议的犬类药物的开发可能为这种类型的药物在适当疾病环境中的药理学行为提供有价值的见解。此外，将单域抗体与其他癌症治疗剂物理结合，可能为免疫分子对抗癌症生长提供一种新的途径。这项拟议的技术有可能为所有类型的患者提供量身定制的癌症治疗。因此，这一最先进的技术进步有可能迅速为所有癌症患者带来新颖有效的产品，具有显著的商业和社会影响潜力。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。